Condition: Neuroblastoma, Recurrent, Refractory · Sponsor: Nanjing Children's Hospital
This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, preliminary efficacy, pharmacokinetics of universal T-cells engineered with chimeric natural killer receptor (CNK-UT) to treat the patients with relapsed/refractory Neuroblastoma.
This description comes directly from the study's public registry record.
Fang Yongjun, Prof. · 025-52862937 · fyj322@189.com
Always discuss trial participation with your own doctor first.
| Nanjing Children's Hospital | Nanjing, Jiangsu, China | Recruiting |
| Nanjing | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06751134